Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy

Clinical and Experimental Dermatology

Volumn 36, Issue 6, 2011, Pages 645-651

  Lam, M ^a   Hsia, A H ^a   Liu, Y ^b   Guo, M ^b   Swick, A R ^a   Berlin, J C ^a   McCormick, T S ^a   Kenney, M E ^b   Oleinick, N L ^c   Cooper, K D ^a,d   Baron, E D ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHTHALOCYANINE; SILICON PHTHALOCYANINE 4; UNCLASSIFIED DRUG;

ADULT; CLINICAL EFFECTIVENESS; CONFOCAL LASER MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; MALE; NORMAL HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SKIN PENETRATION;

ADMINISTRATION, TOPICAL; ADULT; DIFFUSION CHAMBERS, CULTURE; FEMALE; HUMANS; INDOLES; MALE; MEMBRANES, ARTIFICIAL; MICROSCOPY, CONFOCAL; ORGANOSILICON COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; YOUNG ADULT;

EID: 79960616079     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03989.x     Document Type: Review

References (22)

1. Sibata C, Colussi V, Oleinick N, Kinsella T,. Photodynamic therapy in oncology. Expert Opin Pharmacother 2001; 2: 917-27. (Pubitemid 32750348)
2. Dougherty T,. An update on photodynamic therapy applications. J Clin Laser Med Surg 2001; 20: 3-7. (Pubitemid 34174326)
3. Bissonnette R, Tremblay J, Juzenas P, et al. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol 2002; 119: 77-83. (Pubitemid 35304394)
4. Ibbotson S,. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146: 178-88. (Pubitemid 34264385)
5. Oleinick N, Morris R, Belichenko I,. Apoptosis in response to photodynamic therapy: what, where, why and how. Photochem Photobiol Sci 2002; 1: 1-21. (Pubitemid 37069701)
6. Oleinick N, Evans H,. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998; 150: S146-56. (Pubitemid 28519059)
7. Dougherty T, Gomer C, Henderson B, et al. Photodynamic therapy: review. J Natl Cancer Inst 1998; 90: 889-902.
8. Dougherty T, Cooper M, Mang T,. Cutaneous phototoxic occurrences in patients receiving photofrin. Lasers Surg Med 1990; 10: 485-8. (Pubitemid 20366419)
9. Moriwaki S, Misawa J, Yoshinari Y, et al. Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). Photodermatol Photoimmunol Photomed 2001; 17: 241-3. (Pubitemid 32834293)
10. Wang I, Bendsoe N, Klinteberg C, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40. (Pubitemid 32374789)
11. Coors E, Driesch Pvd,. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2004; 50: 363-7. (Pubitemid 38316128)
12. Szeimies R, Landthaler M, Karrer S,. Non-oncologic indications for ALA-PDT. J Dermatolog Treat 2002; 13: S13-18. (Pubitemid 34665809)
13. Holmes M, Dawe R, Ferguson J, Ibbotson S,. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150: 337-40. (Pubitemid 38352473)
14. Wiegell SR, Skiveren J, Phillipsen PA, Wulf HC,. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008; 158: 727-33. (Pubitemid 351415749)
15. Oleinick N, Antunez A, Clay M, et al. New phthalocyanine photosensitizers for photodynamic therapy. Photochem Photobiol 1993; 57: 242-7.
16. Egorin M, Zuhowski E, Sentz D, et al. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc 4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent. Cancer Chemother Pharmacol 1999; 44: 283-94. (Pubitemid 29402197)
17. Meingassner JG, Aschauer H, Stuetz A, Billich A,. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 2005; 14: 752-7. (Pubitemid 41419462)
18. Madision KC,. Barrier function of the skin. 'la raison d'être' of the epidermis. J Invest Dermatol 2003; 121: 231-41.
19. Fartasch M,. Epidermal barrier in disorders of the skin. Microsc Res Tech 1997; 38: 361-72. (Pubitemid 27377648)
20. Usuda J, Chiu S, Murphy E, et al. Domain-dependent photodamage to Bcl-2. J Biol Chem 2003; 278: 2021-9.
21. Morris R, Azizuddin K, Lam M, et al. Fluorescence resonance energy transfer reveals a binding site of a photosensitizer for photodynamic therapy. Cancer Res 2003; 63: 5194-7. (Pubitemid 37139826)
22. Lam M, Oleinick NL, Nieminen AL,. Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization. J Biol Chem 2001; 276: 47379-86.